rfxcel extended its partnership with Navitas Life Sciences (“Navitas”) to enable customers to meet obligations under the European Falsified Medicines Directive (EU FMD), U.S. Drug Supply Chain Security Act (DSCSA), and other serialization requirements. The advanced and simple to use features of the Navitas traceREADY™ edge system are now integrated with rfxcel’s Traceability System (rTS™).
“The new capability provides a truly full-service, one-stop capability for distributors, manufacturers, and the many companies [that] have a complex hybrid of both operations. Edge and re-work activities during manufacturing and supply can now be handled directly and smoothly in our system. As global regulations increasingly affect distribution as well as manufacture of medicines, we are positioned to offer what customers need,” says Glenn Abood, CEO of rfxcel.
“We are pleased to strengthen our successful relationship with rfxcel. Our fully integrated solution now provides customers with significant cost and performance efficiencies. We look forward to taking our solution to the global market and deliver enhanced value to our customers,” says Ram Yeleswarapu, President, Navitas Life Sciences.
rfxcel provides SaaS-based track-and-trace products. Its platform enables companies to protect patients, comply with regulatory mandates, and gain visibility into their supply chain. Navitas Life Sciences leverages industry insights, process consulting, technology, and core operational capabilities to deliver clinical, regulatory and safety solutions and successful outcomes to clients.